# Cormorant Asset Management

Cormorant Asset Management is an Asset Manager based in Boston, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Boston, United States
- **Region:** North America
- **Address:** 200 Clarendon Street, 50th Floor, Boston, MA 02116, United States
- **Founded:** 2013
- **Assets under management:** Undisclosed
- **Website:** www.cormorant-asset.com
- **LinkedIn:** https://www.linkedin.com/company/cormorant-asset-management

## Regulatory record

- **CRD number:** 167820
- **SEC file number:** 801-79513
- **Registration status:** Registered
- **Reports private funds:** Yes
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/167820

## About

Cormorant Asset Management is an SEC-registered investment adviser in Boston, MA, registered since 2014. The firm manages approximately $3.8 billion in assets. It has 12 employees and 3 investment advisers.

## Sectors

- Healthcare Services
- Digital Health

## People

- Bihua Chen — Founder

## Questions

### How does Cormorant Asset Management differ from a pure-play biotech venture capital firm?

Cormorant invests across both private and public life-sciences companies through a single platform. Where a typical biotech VC exits at IPO, Cormorant can hold and even add to positions through PIPEs and public-market trading, using the same underlying research to cover the full lifecycle of a therapeutic company.

### Who makes the investment decisions at Cormorant?

Bihua Chen founded the firm in 2013 and sets the investment direction. The firm describes a team-based research approach but does not publicly name a separate CIO or investment committee. The research process itself prioritizes drug-level and technology-level analysis rather than macro sector calls.

### Does Cormorant participate in fund commitments or only direct deals?

Cormorant's disclosed public and private equity activity emphasizes direct investments into operating biotechnology companies, including venture rounds, crossover financings, and PIPEs. The firm does not publicly describe a fund-of-funds program or commitments to third-party venture managers.

### What type of therapeutics does Cormorant typically invest in?

Cormorant's public positioning is broad across biotechnology and life sciences. The therapeutic remit has historically ranged from small-molecule drug discovery to biologics and platform technologies, with an analytical emphasis on clinical-trial rigor, mechanism-of-action clarity, and competitive-differentiation potential rather than a single disease-area specialization.

## Related profiles

- [Corlex Capital](https://altss.com/profile/corlex-capital)
- [Cornerpost Properties](https://altss.com/profile/cornerpost-properties)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/cormorant-asset-management

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology